New York, NY (PRWEB) August 09, 2012
Medmeme, LLC., a global leader in comprehensive, integrated medical and science information database platforms, has released ten new syndicated TrendsmemeTM Reports. Based on analysis from the Medmeme database, each of the ten reports is focused on the three most current years of activity of a specific therapeutic area. They cover activities and involvement of 92 individual companies – what they have done and are doing, success factors, game-changers, wild cards, potential new treatment success, and the odds for success in the marketplace. Twenty-nine of the companies, among the others, and some of the therapeutic categories in which they work (and indications) are:
Virology (HIV, HCV, HPV) – Abbott, Bristol-Myers Squibb, Gilead Sciences, GlaxoSmithKline, Merck & Co., Roche, Vertex Pharmaceuticals.
Neuroscience – Psychiatric Disease (depression, schizophrenia, anxiety) - Eli Lilly, Janssen, Johnson & Johnson, Pfizer, AstraZeneca, BristolMyers - Squibb, Lundbeck, Forest.
Respiratory Diseases (asthma, COPD, PAH) - GlaxoSmithKline, Novartis, Roche, Merck, AstraZeneca, Boehringer Ingelheim, Nycomed, Actelion, United Therapeutics, Gilead, Pfizer.
Neuroscience-Neurological Diseases (AD, PD, MS) – Janssen, Pfizer, Lundbeck, Forest, GlaxoSmithKline, Eli Lilly, Bayer, Sanofi, Novartis, Biogen Idec, UCB Pharmaceuticals, Acorda, Teva, Eisai, Merck-Serono.
Immune and Inflammatory Diseases (RA, IBD, SLE) – Pfizer, Amgen, Johnson & Johnson, Abbott, Roche, Merck, Biogen, AstraZeneca, Eli Lilly, Novartis, Regeneron, GlaxoSmithKline, Astellas, Sanofi.
Oncology – Hematological Cancers (MM, AML, NHL) - Celgene, Novartis, Takeda/Millennium, Merck, Bristol-Myers Squibb, Roche, Pfizer, GlaxoSmithKline, Sanofi, Abbott.
Metabolic Disorders (type 2 diabetes, metabolic syndrome, obesity) - Merck, Lilly, Novo Nordisk, Bristol-Myers Squibb, Takeda Pharmaceutical, Pfizer, Sanofi, GlaxoSmithKline, Amylin, Johnson & Johnson.
Infectious Disease – Antimicrobials (pneumonia, tuberculosis, malaria) - Novartis, GlaxoSmithKline, Johnson & Johnson (through subsidiary Janssen), Sanofi, Pfizer, among others.
Oncology – Solid Tumors (breast cancer, NSCLC, pancreatic cancer, melanoma) - Roche, Pfizer, Novartis, GlaxoSmithKline, AstraZeneca, Eli Lilly, Bristol-Myers Squibb, Amgen, Boehringer Ingelheim, Eisai, Merck.
Cardiology (hypertension, congestive heart failure (CHF), and hyperlipidemia) - Bristol-Myers Squibb, Novartis, Merck, Pfizer, Abbott Laboratories, AstraZeneca.
A primary purpose of the reports is to provide competitive intelligence. For each category the reports focus sharply on disease burden, indication trends, treatment patterns, R&D activities (including discussion of new drug mechanisms and combination drugs with broader coverage), current company strategies (including acquisitions, mergers and partnering that gives smaller companies new opportunities), still unmet needs that represent treatment and marketplace opportunities.
The information, data, charts and graphs used in the reports are drawn directly from the Medmeme database platforms which contain comprehensive profiles of 1.5+ million scientists, physicians (KOLs), and experts, 600,000+ clinical trials in 50 countries, 6.3 million+ medical meeting presentations, abstracts from 5,100+ medical journals, plus information on almost a million grants and patents each, drugs, medical societies, and the top medical institutions, including mapping of relationships of people, institutions, companies. TrendsmemeTM Reports are a direct derivative of the TrendsmemeTM platform.
A syndicated TrendsmemeTM Report can be purchased separately, or with other reports in the series at discounted pricing. To learn more, contact us, or see our website, http://www.medmeme.com/products/syndicated-reports/reports/trendsmeme-reports
Yan Barshay, Executive Vice President
Ray Wright, Vice President, Sales
+ 1 508-278-4595